Industry News

DaVita HealthCare Partners Inc. announced today that it will hold its quarterly conference call to discuss second quarter results on Monday, August 8, 2016, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita HealthCare Partners IR web page."/>
DaVita HealthCare Partners Inc. Schedules 2nd Quarter 2016 Investor Conference Call
Exalenz Bioscience Ltd., which develops diagnostic systems for digestive conditions based on exhaled breath, announced the success of its NIS 23.5 million rights offering implemented yesterday. 94.2% of the rights were realized, 71.2% of them by Mori Arkin, Exalenz's chief supporter for over a decade, during the highs and lows. At present, Exalenz is traded at a market cap of NIS 65.1 million. Share price is 2% lower than the issue..."/>
Exalenz Bioscience raises NIS 23.5m in TASE offering [Globes, Tel Aviv, Israel]
Second Sight Medical Products, Inc., the developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, today announced positive five-year outcomes associated with patients using the Argus ® II Retinal Prosthesis System."/>
Second Sight Announces Positive Five-Year Data from Argus II Retinal Prosthesis System
Centene Corp., which plans to add more than 1..."/>
Is Clayton emerging as the St. Louis region's new 'downtown'? [St. Louis Post-Dispatch]
CytRx Corporation concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at No class has been certified in the above action."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of CytRx Corporation and Advises Investors with Losses to Contact the Firm
Latest launch carried fungi from Chernobyl [Orlando Sentinel]
CytRx Corporation securities between November 18, 2014, and July 11, 2016, inclusive. CytRx investors have sixty days from the date of this notice to file a lead plaintiff motion. Investors suffering losses on their CytRx investments are encouraged to contact Lesley Portnoy of..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
Apollo Medical Holdings, Inc., an integrated population health management company, today announced the appointment of Mihir Shah, CPA as Chief Financial Officer effective July 21, 2016.. Shah is a seasoned healthcare executive with over 10 years of experience in the healthcare services sector. His expertise includes leadership in finance roles within the managed care, post-acute care and hospice/palliative care sector, as well as..."/>
Apollo Medical Holdings Appoints Mihir Shah As Chief Financial Officer
Eagle Pharmaceuticals Inc. securities between February 23, 2016 and March 18, 2016, inclusive. Eagle investors have until August 1, 2016 to file a lead plaintiff motion."/>
GPM Reminds Investors of the August 1 Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
Ossur Hf :Transactions in relation to share buyback program
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for TRUBERZI ® in the European Union. 4 TRUBERZI ® is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea in adults. 1 In two pivotal trials, TRUBERZI ® significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and..."/>
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Emergent BioSolutions, Inc. concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 19, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm
Coherus BioSciences, Inc., today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the results for the quarter and provide a general business update.. Financial results will be released after market close on Tuesday, August 9, 2016 and posted at"/>
Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th
PTC Therapeutics, Inc. today announced global regulatory updates on Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy and nonsense mutation cystic fibrosis. European update on Translarna for nmDMD. Over the last several months, PTC has been engaged in constructive discussions with the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding the renewal of..."/>
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren)
Centene Corp., which plans to add more than 1..."/>
Is Clayton emerging as the St. Louis region's new 'downtown'? [St. Louis Post-Dispatch]
Press Ganey Holdings, Inc., today announced that it will hold a conference call on Tuesday, August 2, 2016, at 8:30 a.m. Eastern Time to review the Company's second quarter 2016 financial results. A press release announcing the second quarter financial results will be issued after the close of market trading on Monday, August 1, 2016.. To participate in the company's live conference call and webcast, please dial 877-201-0168 using conference code number 28532174, or..."/>
Press Ganey Holdings, Inc. Announces Second Quarter 2016 Earnings Conference Call
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Neal Walker, President and CEO, will ring the Closing Bell."/>
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
Quality Systems, Inc. will release its fiscal 2017 first quarter operating results on Thursday, July 28, 2016 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-900-9499 or 937-502-2136 for international callers, and referencing participant code 51021073 approximately 15 minutes prior to the call."/>
Quality Systems, Inc. to Host Fiscal 2017 First Quarter Results Conference Call
ITC Ltd has appointed Sanjiv Puri, a wholetime director of the company, as chief operating officer with immediate effect, the company said in a filing to the Bombay Stock Exchange. On 6 December, Puri took over as executive director from 6 December, replacing P.V. Before that, Puri was the president of ITC's packaged goods business that accounts for about 80% of ITC's business."/>
Sanjiv Puri, new ITC COO, seen as Deveshwar's successor [Mint, New Delhi]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology774 Articles
Financials742 Articles
Consumer Discretionary655 Articles
Industrials488 Articles
Health Care479 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at